Hormone Insight Editorial Team

Clinical archive

Landmark Cardiovascular Outcomes

CREDENCE: Canagliflozin Reduces Kidney Failure by 30% in Type 2 Diabetes and Albuminuric Nephropathy

The CREDENCE trial demonstrated that canagliflozin reduced the composite of end-stage kidney disease, doubling of serum creatinine, or renal or cardiovascular death by 30% in patients with type 2 diabetes and albuminuric chronic kidney disease, becoming the first dedicated renal outcomes trial to demonstrate that an SGLT2 inhibitor could substantially slow the progression of diabetic nephropathy.

Landmark Cardiovascular Outcomes

DECLARE-TIMI 58: Dapagliflozin Reduces Heart Failure Hospitalisation Across a Broader Type 2 Diabetes Population

The DECLARE-TIMI 58 trial demonstrated that dapagliflozin did not reduce 3-point MACE compared with placebo but significantly reduced the composite of cardiovascular death or hospitalisation for heart failure, driven entirely by a 27% reduction in heart failure hospitalisation, in the largest and most broadly representative SGLT2 inhibitor cardiovascular outcomes trial conducted to date.

Subscribe now

Welcome to Hormone Insight. Our mission is to support clinical decision-making with accessible, evidence-based insights from recent studies and trials.

© 2024-2026 Hormone Insight. All rights reserved.